SR One

SR One, a leading trans-Atlantic biotechnology venture capital firm, focuses on translating innovative science into transformative medicines. Originally established in 1985 as the venture capital arm of GlaxoSmithKline (GSK), SR One completed its spin-out from GSK in 2020, marking a significant milestone in its journey. The firm successfully raised a $500 million fund, making it the largest first-time VC fund focused on U.S. and European biotech startups in 2020. This was followed by a second fund of $600 million, bringing their total assets under management to over $1.5 billion. SR One's investment strategy centers on building and supporting elite biotechnology companies through a "back-and-build" approach, providing both financial and operational support to advance programs through critical development stages. The firm operates out of key biotech hubs in Redwood City, California, Philadelphia, Pennsylvania, and London, UK, which allows it to leverage opportunities and provide regional expertise. Key team members include CEO Simeon George, who has been with the firm since 2007 and has played a pivotal role in several major investments such as CRISPR Therapeutics and Principia Biopharma. SR One's leadership and venture partners bring extensive experience in biotech investments and company creation.